13
Feb
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26% Mumbai (Maharashtra) [India], February 13: JB Pharma, one of the fastest growing pharmaceutical companies in India, announced record revenue growth of 32% to Rs. 793 crore in Q3 FY23. Operating EBITDA (Earnings Before Interest Depreciation and Taxes) increased by 26% to Rs. 193 crore as compared to Rs. 153 crore. Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%. Commenting on financial results, Mr. Nikhil Chopra, CEO and Wholetime Director, JB Pharma mentioned,…
